AVITA Medical, Inc. $RCEL

What the company doesAI summary of filing

AVITA Medical is a medical device company that develops and commercializes products for acute wound care, including burns, traumatic injuries, and surgical wounds. The company's lead product is RECELL, an FDA-approved autologous cell harvesting device that enables clinicians to create a suspension of a patient's own skin cells for wound treatment, which the company has commercialized since January 2019. RECELL is complemented by two additional wound care products: PermeaDerm, a biosynthetic wound matrix distributed under agreement with Stedical, and Cohealyx, a collagen-based dermal matrix distributed under agreement with Regenity and launched commercially in April 2025. The company is revenue-generating, with RECELL approved for thermal burns, full-thickness skin defects, and vitiligo repigmentation, and generates revenue through device sales to hospitals, burn centers, trauma centers, and surgical centers. [10-K 2026-02-12]

Segments: RECELL, PermeaDerm, Cohealyx